These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 39059185)

  • 1. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial.
    Mukherjee S; Qi C; Shaw R; Jones CM; Bridgewater JA; Radhakrishna G; Patel N; Holmes J; Virdee PS; Tranter B; Parsons P; Falk S; Wasan HS; Ajithkumar TV; Holyoake D; Roy R; Scott-Brown M; Hurt CN; O'Neill E; Sebag-Montefiore D; Maughan TS; Hawkins MA; Corrie P
    Eur J Cancer; 2024 Sep; 209():114236. PubMed ID: 39059185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).
    Strauss VY; Shaw R; Virdee PS; Hurt CN; Ward E; Tranter B; Patel N; Bridgewater J; Parsons P; Radhakrishna G; O'Neill E; Sebag-Montefiore D; Hawkins M; Corrie PG; Maughan T; Mukherjee S
    BMC Cancer; 2019 Feb; 19(1):121. PubMed ID: 30717707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.
    Hurt CN; Falk S; Crosby T; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T; Mukherjee S
    Br J Cancer; 2017 May; 116(10):1264-1270. PubMed ID: 28376080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, Phase I Study of Nivolumab Combined with
    Wainberg ZA; Hochster HS; Kim EJ; George B; Kaylan A; Chiorean EG; Waterhouse DM; Guiterrez M; Parikh A; Jain R; Carrizosa DR; Soliman HH; Lila T; Reiss DJ; Pierce DW; Bhore R; Banerjee S; Lyons L; Louis CU; Ong TJ; O'Dwyer PJ
    Clin Cancer Res; 2020 Sep; 26(18):4814-4822. PubMed ID: 32554514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer.
    Shabason JE; Chen J; Apisarnthanarax S; Damjanov N; Giantonio B; Loaiza-Bonilla A; O'Dwyer PJ; O'Hara M; Reiss KA; Teitelbaum U; Wissel P; Drebin JA; Vollmer C; Kochman M; Mick R; Vergara N; Jhala N; Doucette A; Lukens JN; Plastaras JP; Metz JM; Ben-Josef E
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):609-614. PubMed ID: 29362902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.
    Feliu J; Jorge Fernández M; Macarulla T; Massuti B; Albero A; González González JF; Quintero-Aldana G; Delgado-Mingorance JI; Fernández Montes A; García Piernavieja C; Valladares-Ayerbes M; López Muñoz AM; Mondéjar Solís R; Vicente P; Casado Gonzalez E; González Cebrián I; López-Vivanco G
    Cancer Chemother Pharmacol; 2021 Apr; 87(4):543-553. PubMed ID: 33452559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy and radiotherapy for advanced pancreatic cancer.
    Chin V; Nagrial A; Sjoquist K; O'Connor CA; Chantrill L; Biankin AV; Scholten RJ; Yip D
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011044. PubMed ID: 29557103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
    Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T
    Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
    Holyoake DLP; Warren DR; Hurt C; Aznar M; Partridge M; Mukherjee S; Hawkins MA
    Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):418-426. PubMed ID: 29602584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
    Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
    Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
    Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.
    Arscott WT; Nead KT; Bear A; Venigalla S; Shabason J; Lukens JN; Plastaras JP; Wojcieszynski A; Metz J; O'Hara M; Reiss KA; Teitelbaum U; Loaiza-Bonilla A; Drebin J; Lee MK; Shroff SG; Ben-Josef E
    Am J Clin Oncol; 2021 Sep; 44(9):469-474. PubMed ID: 34310350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
    Hingorani SR; Zheng L; Bullock AJ; Seery TE; Harris WP; Sigal DS; Braiteh F; Ritch PS; Zalupski MM; Bahary N; Oberstein PE; Wang-Gillam A; Wu W; Chondros D; Jiang P; Khelifa S; Pu J; Aldrich C; Hendifar AE
    J Clin Oncol; 2018 Feb; 36(4):359-366. PubMed ID: 29232172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study.
    Chang C; Li X; Cao D
    BMC Cancer; 2021 May; 21(1):545. PubMed ID: 33985455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis.
    Takahara N; Nakai Y; Ishigami H; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Yamashita H; Isayama H; Seto Y; Koike K
    Invest New Drugs; 2021 Feb; 39(1):175-181. PubMed ID: 32772340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
    Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL
    Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
    Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
    Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer.
    Wilson JM; Fokas E; Dutton SJ; Patel N; Hawkins MA; Eccles C; Chu KY; Durrant L; Abraham AG; Partridge M; Woodward M; O'Neill E; Maughan T; McKenna WG; Mukherjee S; Brunner TB
    Radiother Oncol; 2016 May; 119(2):306-11. PubMed ID: 27117177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.